glucagon retatrutide Research Guide: What the Phase 2 Trial Data Reported (2026) Retatrutide is one of the

In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]

In a clinical trial, people who initiated and stayed on the highest dose of Foundayo lost an average of about 27 pounds, compared with about 2 pounds on a placebo

Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, et al

Symptoms can include stomach pain, fever and clay-colored stools

Researchers investigating incretin-based compounds use Retatrutide as a reference molecule when comparing receptor selectivity and downstream signaling effects across the GLP-1/GIP/glucagon receptor family